Answers are grounded in this paper and cite their sources.
Zoonotic and endemic veterinary diseases remain important constraints on food security, public health, and pandemic preparedness. Conventional vaccine platforms, including live-attenuated, inactivated, and subunit vaccines, may require substantial development time and can have limited flexibility when new pathogens emerge. mRNA vaccines offer an alternative platform with potential advantages in rapidly developing and modifying vaccines against veterinary and zoonotic diseases. Advances in cap engineering, untranslated region optimization, codon design, and nucleoside modification have enhanced antigen expression while reducing undesirable innate immune activation. Self-amplifying RNA platforms may further reduce antigen requirements through intracellular RNA amplification, thereby lowering manufacturing costs. However, translating these technologies from human to veterinary medicine involves several species- and application-specific constraints. Lipid nanoparticle delivery remains inefficient, with reported endosomal escape rates of approximately 1–2%. Pre-existing anti-PEG immunity and species-dependent pharmacokinetic characteristics may affect repeated administration in livestock. Adequate thermostability is also important for field deployment, particularly where cold-chain infrastructure is limited. In addition, DIVA compatibility requirements and differences among regulatory frameworks, including those of the USDA, EMA-CVMP, and national authorities, may complicate product development and approval. This review examines the molecular, immunological, manufacturing, and regulatory evidence relevant to mRNA vaccination against four priority veterinary and zoonotic pathogens: African swine fever virus, porcine reproductive and respiratory syndrome virus, animal coronaviruses, and pestiviruses. These case studies are used to examine the principal translational constraints currently affecting veterinary mRNA vaccine development. The review also considers the potential application of artificial intelligence-assisted antigen design, decentralized manufacturing, and broadly protective vaccine strategies to translate mRNA technology from human medicine to veterinary and One Health applications.
No takes yet. Share an insight, caveat, or question.
Ashfaq et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: